Shane has particular expertise advising on corporate strategy and transactions (financings, partnering, M&A). He is currently CEO at F2G, a biotech company focused on developing new anti-fungal agents. He has extensive experience building, financing, and managing early and mid size growth companies. During the past 10 years he has arranged sources and terms for over $100 million in equity (and subordinated debt) funds, as well as over $50 million in senior debt transactions. In addition, he has been responsible for designing, implementing and managing financial accounting and management systems for two rapidly growing venture financed companies. Shane has extensive educational experience in accounting, finance, law and business management. He has participated on a senior level with rapidly growing biotechnology and other life science businesses in financing strategy, growth strategy and mergers and acquisitions. Shane was previously the founding Chief Executive of two venture-backed firms in the United States. His strong commercial sense was key in growing his past venture from loss making to an annual turnover of $65m in less than 2.5 years.

Raman has advised on healthcare business development and financing transactions totalling over $65 million. He founded ATPBio in 2002, and has built a substantial network with CEO/ CFO level in biotech and healthcare companies and with senior members of the investment community. Operational roles include Head of Corporate Development at a UK biotech, F2G Ltd. Previously he was a senior biotech analyst at a London investment bank, where he identified several successful healthcare private equity investment opportunities. Raman qualified as a medical doctor from the Queens Medical Centre, University of Nottingham, UK. He practiced clinical medicine for six years in A&E and general medicine. Raman also writes a blog on trends in biotech business, "ATPblog". This is read by over 1000 senior level life science professionals including CEOs, CFOs, VCs, directors and entrepreneurs.

Jeff has considerable expertise in financial and operational management, including 11 years at Partner /Director level. He is a founder and Managing Partner of Kelly, Bamman & Partners, Ltd., a boutique investment bank. He has participated in raising over $30 million in private equity and played a key role in the licensing of several drug programs from a U.S. biotech in order to structure a spin-out. He also has been involved in M&A analyses and evaluation, and implementation of operational systems for finance, accounting, personnel and IT. Previously, he was the Vice President of Global Support Services for F5 Networks where he grew the Services Organization from 30 to a team of 125 professionals and quadrupled service revenue. Previously, he has held positions as Director of Contract Consulting Services with Excell Data Corporation, and a variety of senior positions at Digital Equipment Corporation. Jeff earned his MBA in Finance with the Anderson School of Management at UCLA, and is a former CPA.

Frank has around 20 years of senior management experience gained from GlaxoSmithKline, Amersham Biosciences (as a Vice-President of R&D) and several start-up firms. He is a (co)-Founder of two biotechnology firms: Smart Holograms (Cambridge, UK) and Aurora Biosciences (San Diego, USA), which had a peak market capitalization of $3.0 billion and was later sold to Vertex Pharmaceuticals for circa. $600 million. Frank has raised circa. $30 million in venture capital, $40 million via an IPO on NASDAQ and has delivered many major, commercial partnerships with global, Life Sciences firms - resulting in committed capital of almost $350 million. He is currently Managing Director of Life Sciences Consultancy Limited (Glasgow, UK), and is on the Board of Biochannel Partners Limited (Glasgow, UK) and the Advisory Board of Warwick Business School. Frank has a BSc and PhD in Microbiology from the University of Glasgow and a MBA from Warwick Business School.